Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2019 (← Previous) (Next →)

Filing Date: Jan 21, 2020

Total Value: $331.8B (100.0% shares, 0.0% debt)

Holdings (7)

CRSP CRISPR Therapeutics AG 77.2%

Value $256.1B Shares 4,205,615 Est. Cost $40.26 Unrealized +35.6%

VCYT Veracyte, Inc. 10.1%

Value $33.65B Shares 1,205,407 Est. Cost $11.03 Unrealized +134.7%

— Gritstone Oncology, Inc. 8.4%

Value $27.83B Shares 3,102,929 Est. Cost $11140.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 2.6%

Value $8.751B Shares 2,215,384 Est. Cost $20.09 Unrealized -82.7%

— Second Sight Medical Products, Inc. 1.0%

Value $3.336B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— CymaBay Therapeutics, Inc. 0.3%

Value $1.066B Shares 543,753 Est. Cost $9871.60 Unrealized —

— Clovis Oncology, Inc. 0.3%

Value $1.062B Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,205,615	$256.1B	77.2%	$40.26	+35.6%	Common Stock	H17182108
VCYT	Veracyte, Inc.	1,205,407	$33.65B	10.1%	$11.03	+134.7%	Common Stock	92337F107
—	Gritstone Oncology, Inc.	3,102,929	$27.83B	8.4%	$11140.00	—	Common Stock	39868T105
OCUL	Ocular Therapeutix, Inc.	2,215,384	$8.751B	2.6%	$20.09	-82.7%	Common Stock	67576A100
—	Second Sight Medical Products, Inc.	4,492,975	$3.336B	1.0%	$1210.00	—	Common Stock	81362J100
—	CymaBay Therapeutics, Inc.	543,753	$1.066B	0.3%	$9871.60	—	Common Stock	23257D103
—	Clovis Oncology, Inc.	101,855	$1.062B	0.3%	$56000.00	—	Common Stock	189464100